Clearside Biomedical: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Clearside Biomedical (NASDAQ:CLSD) reported Q3 earnings with an EPS of $-0.15, which was in line with estimates. Revenue increased by $593 thousand compared to the same period last year. The company's stock price dropped 6.6% the day after missing EPS estimates last quarter.
November 13, 2023 | 9:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Clearside Biomedical reported Q3 earnings with an EPS of $-0.15, in line with estimates, and a revenue increase of $593 thousand from the same quarter last year.
The EPS meeting estimates suggests a neutral impact on the stock price in the short term. However, the increase in revenue could be viewed positively. The previous quarter's miss and subsequent stock drop may cause some investors to be cautious.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100